MedTrace Logo

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

NCT04667312 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2023-10-02

No results posted yet for this study

Summary

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in the United Kingdom (the CODAK study). Physicians who have treated patients who have locally advanced, unresectable Stage III NSCLC with durvalumab will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients receiving durvalumab through the Early Access Programme (EAP) or post-reimbursement.

Conditions

  • Non-Small Cell Lung Cancer NSCLC

Interventions

DRUG

Durvalumab

Durvalumab

Sponsors & Collaborators

Principal Investigators

  • Kevin Franks · Leeds Teaching Hospitals NHS Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-24
Primary Completion
2022-09-28
Completion
2022-09-28
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04667312 on ClinicalTrials.gov